C
Chanpheng Phommaly
Researcher at Washington University in St. Louis
Publications - 10
Citations - 1055
Chanpheng Phommaly is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Estrogen receptor & Breast cancer. The author has an hindex of 6, co-authored 10 publications receiving 956 citations. Previous affiliations of Chanpheng Phommaly include University of Washington.
Papers
More filters
Journal ArticleDOI
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li,Dong Shen,Jieya Shao,Robert J. Crowder,Wenbin Liu,Aleix Prat,Xiaping He,Shuying Liu,Jeremy Hoog,Charles Lu,Li Ding,Obi L. Griffith,Christopher A. Miller,Dave Larson,Robert S. Fulton,Michelle Harrison,Thomas B. Mooney,Joshua F. McMichael,Jingqin Luo,Yu Tao,Rodrigo Franco Gonçalves,Christopher E. Schlosberg,Jeffrey F. Hiken,Laila Saied,César Sánchez,Therese Giuntoli,Caroline Bumb,Crystal Cooper,R.T. Kitchens,Austin Lin,Chanpheng Phommaly,Sherri R. Davies,Jin Zhang,Megha Shyam Kavuri,Donna McEachern,Yiyu Dong,Cynthia X. Ma,Timothy J. Pluard,Michael Naughton,Ron Bose,Rama Suresh,Reida G. McDowell,Loren S. Michel,Rebecca Aft,William E. Gillanders,Katherine DeSchryver,Richard K. Wilson,Shaomeng Wang,Gordon B. Mills,Ana M. Gonzalez-Angulo,John R. Edwards,Christopher G. Maher,Charles M. Perou,Elaine R. Mardis,Matthew J. Ellis +54 more
TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.
Journal ArticleDOI
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor positive breast cancer
Robert J. Crowder,Chanpheng Phommaly,Yu Tao,Jeremy Hoog,Jingqin Luo,Charles M. Perou,Joel S. Parker,Melinda A. Miller,David G. Huntsman,Li Lin,Jacqueline E. Snider,Sherri R. Davies,John A. Olson,Mark A. Watson,Anthony J. Saporita,Jason D. Weber,Matthew J. Ellis +16 more
TL;DR: Results suggest that PI3K inhibitors should target both p110alpha and p110beta catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER(+) breast cancer.
Journal ArticleDOI
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
César Sánchez,Cynthia X. Ma,Robert J. Crowder,Therese Guintoli,Chanpheng Phommaly,Feng Gao,Li Lin,Matthew J. Ellis +7 more
TL;DR: Estrogen deprivation increased the apoptotic effects ofPI3K and dual PI3K/mTOR inhibitors in ER-positive disease, providing a rationale for PI3k/aromatase inhibitor combinations as first-line therapy.
Journal ArticleDOI
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
Jonathan T. Lei,Jieya Shao,Jin Zhang,Michael D. Iglesia,Doug W. Chan,Jin Cao,Meenakshi Anurag,Purba Singh,Xiaping He,Yoshimasa Kosaka,Ryoichi Matsunuma,Robert J. Crowder,Jeremy Hoog,Chanpheng Phommaly,Rodrigo Franco Gonçalves,Susana Ramalho,Raquel Mary Rodrigues Peres,Nindo Punturi,Cheryl Schmidt,Alex Bartram,Eric Jou,Vaishnavi Devarakonda,Kimberly R. Holloway,W. Victoria Lai,Oliver A. Hampton,Anna Rogers,Ethan Tobias,P Parikh,Sherri R. Davies,Shunqiang Li,Cynthia X. Ma,Vera J. Suman,Kelly K. Hunt,Mark A. Watson,Katherine A. Hoadley,E. Aubrey Thompson,Xi Chen,Shyam M. Kavuri,Chad J. Creighton,Christopher G. Maher,Charles M. Perou,Svasti Haricharan,Matthew J. Ellis +42 more
TL;DR: Transcriptionally active ESR1 fusions trigger both endocrine therapy resistance and metastatic progression, explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective.
Journal ArticleDOI
Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients.
Yiing Lin,Peter S. Goedegebuure,Marcus C.B. Tan,Julia Gross,James P. Malone,Sheng Feng,Justin W. Larson,Chanpheng Phommaly,Kathryn Trinkaus,Raymond R. Townsend,David C. Linehan +10 more
TL;DR: The plasma of patients undergoing surgical resection is surveyed to identify proteins which change in abundance after complete resection of pancreas tumor and these proteins are identified which correlate with post-surgical rapid recurrence of disease.